tbuckley/cabot-search huggingface dataset:
Specific breast-screening programme for childhood cancer survivors following exposure to ionizing radiation
Authors: M. Terenziani, G. Scaperrotta, P. Lepera, C. Meazza, M. Podda, L. Gandola, M. Greco, G. Trecate, F. Spreafico, M. Gennaro
Journal: Journal of Clinical Oncology (2008)

1529 Background: High number of long-term survivors after irradiation develop a second cancer. The aim of this prospective study was to evaluate the long-term risk to develop breast cancer following exposure to ionizing radiation at pediatric age and to compare the sensitivity of clinical breast examination (CBE), mammography (MX) and ultrasonography (US) for screening of such young women. Methods: We identified 86 patients from an institutional database that received chest wall radiotherapy for pediatric cancer. They accepted to be enrolled for an intensive surveillance program: CBE, US and MX were yearly performed. A screening event, that is constituted by three diagnostic procedures (two under 25 years old), takes place in a single day. Overall detection rate of breast cancer per year and sensitivity of the three diagnostic procedures were calculated. Results: Among these women, from April 2004 to May 2007, we identified 8 breast cancers. The age at diagnosis ranged between 26 to 49 yrs. Two cases were stage 0, four were stage I and two were stage II or higher. All but two cases were treated with a total mastectomy because of multifocal disease or extensive intraductal cancer. One death was due to breast cancer. Overall detection rate was 3% per year, ten-fold higher than expected in older women from screening mammography. We found a sensitivity of 50%, 83% and 67% for CBE, MX and US, respectively. Conclusions: This group of female should be considered at increased risk to develop a breast cancer that occurs earlier than expected in general population, when screening programs are not applied for early detection. A specific screening program for such patients should be warranted. We further continue this investigation by adding yearly magnetic resonance as additional tool to improve the tumor detection, especially in dense breast. No significant financial relationships to disclose.
Humans With Atherosclerosis Have Impaired ABCA1 Cholesterol Efflux and Enhanced High-Density Lipoprotein Oxidation by Myeloperoxidase
Authors: Baohai Shao, Chongren Tang, Abhishek Sinha, Philip S. Mayer, George D. Davenport, Nathan Brot, Michael N. Oda, Xue-Qiao Zhao, Jay W. Heinecke
Journal: Circulation Research (2014)

Rationale: The efflux capacity of high-density lipoprotein (HDL) with cultured macrophages associates strongly and negatively with coronary artery disease status, indicating that impaired sterol efflux capacity might be a marker—and perhaps mediator—of atherosclerotic burden. However, the mechanisms that contribute to impaired sterol efflux capacity remain poorly understood. Objective: Our aim was to determine the relationship between myeloperoxidase-mediated oxidative damage to apolipoprotein A-I, the major HDL protein, and the ability of HDL to remove cellular cholesterol by the ATP-binding cassette transporter A1 (ABCA1) pathway. Methods and Results: We quantified both site-specific oxidation of apolipoprotein A-I and HDL’s ABCA1 cholesterol efflux capacity in control subjects and subjects with stable coronary artery disease or acute coronary syndrome. Subjects with coronary artery disease and acute coronary syndrome had higher levels of chlorinated tyrosine 192 and oxidized methionine 148 compared with control subjects. In contrast, plasma levels of myeloperoxidase did not differ between the groups. HDL from the subjects with coronary artery disease and acute coronary syndrome was less able to accept cholesterol from cells expressing ABCA1 compared with HDL from control subjects. Levels of chlorinated tyrosine and oxidized methionine associated inversely with ABCA1 efflux capacity and positively with atherosclerotic disease status. These differences remained significant after adjusting for HDL-cholesterol levels. Conclusions: Our observations indicate that myeloperoxidase may contribute to the generation of dysfunctional HDL with impaired ABCA1 efflux capacity in humans with atherosclerosis. Quantification of chlorotyrosine and oxidized methionine in circulating HDL might be useful indicators of the risk of cardiovascular disease that are independent of HDL-cholesterol.
The paradox of tobacco control
Authors: D. Satcher
Journal: JAMA (1994)

Under the best of circumstances, knowledge brings about changes in behavior and public policy. When thinking about what we know and what we have accomplished in the realm of smoking and health, we perceive a paradox. Decades of careful medical research have documented the hazards of smoking. Social scientists continue to investigate and define the factors that impede efforts to prevent the use of tobacco. We know that nicotine is an addictive substance and that our children are very vulnerable to this addiction. We know that smoking is the single greatest cause of death in the United States.<sup>1</sup>Yet, we are still plagued by an entirely preventable problem, and this is the paradox of tobacco control. To better understand this paradox and perhaps be better able to reconcile what we know and what we do, we have developed a framework that provides an organized approach to categorizing tobacco control
FFR Derived From Coronary CT Angiography in Nonculprit Lesions of Patients With Recent STEMI
Authors: Sara Gaur, Charles A Taylor, Jesper M Jensen, Hans Erik Bøtker, Evald H Christiansen, Anne K Kaltoft, Niels R Holm, Jonathon Leipsic, Christopher K Zarins, Stephan Achenbach, Sophie Khem, Alan Wilk, Hiram G Bezerra, Jens F Lassen, Bjarne L Nørgaard
Journal: JACC. Cardiovascular imaging (2016)
TCT-103 National variation in post-TAVR antithrombotic therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry®
Authors: Matthew W. Sherwood, Amit N. Vora, Sreekanth Vemulapalli, David Dai, Sharif Halim, Todd Kiefer, G.C. Hughes, J. Kevin Harrison
Journal: Journal of the American College of Cardiology (2015)
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Authors: Raffit Hassan, Anish Thomas, Christine Alewine, Dung T. Le, Elizabeth M. Jaffee, Ira Pastan
Journal: Journal of Clinical Oncology (2016)

Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an attractive target for cancer immunotherapy because its normal expression is limited to mesothelial cells, which are dispensable. Several antibody-based therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation. These include antimesothelin immunotoxins (SS1P, RG7787/LMB-100), chimeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A, BMS-986148), live attenuated Listeria monocytogenes-expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies. Two antimesothelin agents are currently in multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line setting and anetumab ravtansine as second-line therapy. Phase II randomized clinical trials of CRS-207 as a boosting agent and in combination with immune checkpoint inhibition for pancreatic cancer are nearing completion. These ongoing studies will define the utility of mesothelin immunotherapy for treating cancer.
Acute leukemia in adult Hispanic Americans: a large-population study
Authors: R Swords, J Sznol, R Elias, J Watts, A Zelent, E Martin, F Vargas, S Bethel-Ellison, E Kobetz
Journal: Blood Cancer Journal (2016)

Acute leukemia (AL) is a diverse group of clonal hematopoietic disorders that are broadly categorized into two types: acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).1, 2, 3 AML is further grouped into acute promyelocytic leukemia (APL, a highly curable disease with a unique and pathognomonic genetic lesion) and non-APL AML. ALL is also further lineage classified into B-cell ALL or T-cell ALL. Unlike older classification systems that defined AL according to how leukemia cells looked and stained under the light microscope,1 the current iteration of the World Health Organization (WHO) classification of hematopoietic neoplasms incorporates cytogenetic and molecular data to provide prognostic and therapeutic information of value to the treating clinician.2, 3 When applied to large-population databases, the WHO framework also provides useful insights into the distribution of AL among ethnic groups, informing on the causative factors of AL, which are at this time poorly understood. For example, in the United States, whites have higher rates of AML compared with other groups.4 B-ALL is uncommon in blacks and Asians, whereas Hispanics have the highest incidence rates (IR) of this leukemia.5 AML appears less common in Hispanics when compared with whites, however, APL appears comparatively more common in Hispanics.6 The varied distribution of AL among these ethnic groups suggests that host susceptibility factors are critical determinants of disease in one group, but not in another. The extent to which the environment interacts with these factors is unknown. In Florida, Hispanics comprise 23.6% of the population, with up to 65% of this group residing in South Florida. About 51% of Hispanics in Florida are native born, 49% are foreign born. In 2015, it is estimated that 3930 new cases of AL will be diagnosed.7 Given the known interaction between ethnicity and AL incidence, we sought for the first time, to better understand the epidemiological patterns of AL distribution throughout Florida. Utilizing the Florida Cancer Data System (FCDS), we analyzed the patterns of B-cell ALL, T-cell ALL, non-APL AML and APL AML among Hispanics and non Hispanic Whites.
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
Authors: Marius M Hoeper, Vallerie V McLaughlin, Joan Albert Barberá, Adaani E Frost, Hossein-Ardeschir Ghofrani, Andrew J Peacock, Gérald Simonneau, Stephan Rosenkranz, Ronald J Oudiz, R James White, Karen L Miller, Jonathan Langley, Julia H N Harris, Christiana Blair, Lewis J Rubin, Jean-Luc Vachiery
Journal: The Lancet Respiratory Medicine (2016)
Power Is Nothing Without Control
Authors: Beatrice Bassetti, Maurizio C. Capogrossi, Giulio Pompilio
Journal: Circulation Research (2016)

A few observation and much reasoning lead to error; many observations and a little reasoning to truth.-Alexis Carrel, Medicine Nobel Prize 1912 C ardiac cell-based therapy, after a peak of untimely expectations of miraculous efficacy exceeding standard clinical practice, has faced the cardiological community and funding bodies with a predictable trough of disillusionment.In the light of more recent progresses, the field is by contrast moving toward a competitive differentiation phase, in which the resolution of the complex matching between potency of cell therapeutics and heart disease pathophysiology has the potential to make a difference for the most challenging unmet clinical needs in cardiovascular medicine.
Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial
Authors: J. A. Garcia, P. Triozzi, P. Elson, M. M. Cooney, A. Tyler, T. Gilligan, R. Dreicer
Journal: Journal of Clinical Oncology (2008)

5143 Background: Ketoconazole (Keto) is an active second-line hormonal maneuver that induces PSA responses in 20–30% of CPPCA patients (pts). In addition to the suppression of testicular and adrenal androgen production, Keto inhibits ADCC, NK cell activity as well as IL-2 synthesis and subsequent T cell proliferation. Lenalidomide (LEN) is an immunomodulatory analogue of thalidomide with significant T cell stimulatory and antiangiogenic properties. We hypothesized that the immune stimulatory activity of LEN might augment the activity of Keto and tested the combination of Keto and LEN. Methods: Eligible CPPCA pts had PSA progression with or without limited bone and soft tissue metastasis. Pts were required to be chemotherapy naive and unexposed to ketoconazole/thalidomide. All pts received Keto at 400mg administered 3 times daily along with LEN 25 mg/day orally on D1–21 of a 28-day cycle. Low-dose aspirin was required for DVT prophylaxis. Endpoints included response, safety and biologic effects, including activation of DCs, Tregs, and Th1 cytokine production. Results: To date 19 of a total planned 34 pts are enrolled (4 with soft tissue disease, 9 with evidence of bone metastases; 6 with PSA-only disease). 18 pts are currently evaluable for response. Median age is 70 years (range, 48–85), median PSA of 12.7 ng/mL (range, 2.6–132.6). Pts have received a median of 2 cycles of treatment (range: 1–10+). Overall, 14 of 18 pts (74%) have experienced some reduction in PSA (3 between 1–30%; 1 between 30–50%; 3 between 50–75%; 1 between 75–90% and 6 >90%). Among pts with measurable disease (4/17), three have achieved a confirmed PR and one SD with tumor volume reduction by RECIST criteria. Seven pts have discontinued therapy (1 PD, 4 toxicity, and 2 withdrew consent). Grade (G) 1–2 fatigue was the most common toxicity observed in 94% of pts. G3 fatigue was observed in 2 pts. Only one pt developed G4 toxicity (CHF). PB cell phenotype analysis and cytokine levels indicate immune activation. Conclusions: The combination of Keto and LEN is relatively well tolerated with clear evidence of antitumor activity. Exploratory immune studies and their correlation with clinical response are underway and will be presented at the meeting. Accrual to this study is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Celgene, Dendreon, Merck, Novartis, Wyett Bayer/Onyx, Pfizer, Wyett Bayer, Celgene, Genentech, Novartis, Pfizer, Wyett
Social-ecological perspectives on breast cancer care seeking patterns in Karnataka, India.
Authors: Arun S. Shet, Suneeta Krishnan, Sandra Mary Travasso, Girish Raju, Sreelatha Meleth, Shiva Kumar
Journal: Journal of Clinical Oncology (2015)

6542 Background: India bears approximately ten percent of the global burden of breast cancer but has lower survival rates than developed countries possibly due to delays in diagnosis and treatment. Early recognition and diagnosis of breast cancer potentially offers the opportunity for treating the early stage disease and potentially improve treatment outcomes. The underlying factors responsible for delays in access to treatment are not well-defined. There are few published studies that attempt to understand the factors that facilitate or impede care-seeking and timely diagnosis and treatment of breast cancer in the Indian context. Methods: Using the social-ecological theory of behaviour, we conducted semi-structured in-depth interviews with 27 breast cancer patients and 22 primary caregivers receiving care at a non-profit tertiary care hospital in Bengaluru, India to understand how care-seeking and the timing of diagnosis and treatment were influenced by multilevel factors, including knowledge and awareness of breast cancer, family and community reactions to symptoms and diagnosis, and availability and access to different types of clinical services. Results: Factors that impeded timely diagnosis and treatment were women's lack of awareness about the signs and symptoms and the need for timely care-seeking, competing family/household priorities, fear of a cancer diagnosis, inconsistent pathways through the healthcare system for diagnosis and treatment, financial constraints, and fear and stigma related to cancer.The main facilitators in care seeking included hope of getting cured, financial and social support from the family. Conclusions: A range of multilevel factors seem to be associated with women's breast cancer care trajectories. Qualitative findings suggest that multifaceted interventions that address knowledge, fear and stigma among individuals, families and communities and that improve access to health care through financial protection may be needed to downstage breast cancer in India.These emerging findings from our qualitative research are being used to develop a quantitative instrument to further study this issue using a more representative sample.
GW27-e0265 A study on the mechanism of the oxidative damage in Ginsenoside Rb1 against the replicative senescence of endothelial cells
Authors: Bin Zhou, Yesheng Ling, Lin Wu, Shujie Yu, Dinghui Liu, Min Wang, Yong Liu, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
Acute Myeloid Leukemia Alters The Mesenchymal Stem Cell Potential Of The HSC Niche: Evidence For Modulation By β-Adrenergic Signals
Authors: Maher Hanoun, Dachuan Zhang, Sandra Pinho, Toshihide Mizoguchi, Julie Lacombe, Scott A. Armstrong, Ulrich Duehrsen, Paul S. Frenette
Journal: Blood (2013)
Are MSCs Stem Cells? Demonstration of in Vitro and in Vivo Stem Cell Properties of Highly Enriched linneg/CD45neg/CD271pos/CD140alow/Neg Mesenchymal Stromal Cells from Adult Human Bone Marrow
Authors: Roshanak Ghazanfari, Hongzhe Li, Dimitra Zacharaki, Simón Méndez-Ferrer, Stefan Scheding
Journal: Blood (2014)
Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial
Authors: Rajesh Patel, Michael J Sweeting, Janet T Powell, Roger M Greenhalgh
Journal: The Lancet (2016)

Short-term survival benefits of endovascular aneurysm repair (EVAR) versus open repair of intact abdominal aortic aneurysms have been shown in randomised trials, but this early survival benefit is lost after a few years. We investigated whether EVAR had a long-term survival benefit compared with open repair.We used data from the EVAR randomised controlled trial (EVAR trial 1), which enrolled 1252 patients from 37 centres in the UK between Sept 1, 1999, and Aug 31, 2004. Patients had to be aged 60 years or older, have aneurysms of at least 5·5 cm in diameter, and deemed suitable and fit for either EVAR or open repair. Eligible patients were randomly assigned (1:1) using computer-generated sequences of randomly permuted blocks stratified by centre to receive either EVAR (n=626) or open repair (n=626). Patients and treating clinicians were aware of group assignments, no masking was used. The primary analysis compared total and aneurysm-related deaths in groups until mid-2015 in the intention-to-treat population. This trial is registered at ISRCTN (ISRCTN55703451).We recruited 1252 patients between Sept 1, 1999, and Aug 31, 2004. 25 patients (four for mortality outcome) were lost to follow-up by June 30, 2015. Over a mean of 12·7 years (SD 1·5; maximum 15·8 years) of follow-up, we recorded 9·3 deaths per 100 person-years in the EVAR group and 8·9 deaths per 100 person-years in the open-repair group (adjusted hazard ratio [HR] 1·11, 95% CI 0·97-1·27, p=0·14). At 0-6 months after randomisation, patients in the EVAR group had a lower mortality (adjusted HR 0·61, 95% CI 0·37-1·02 for total mortality; and 0·47, 0·23-0·93 for aneurysm-related mortality, p=0·031), but beyond 8 years of follow-up open-repair had a significantly lower mortality (adjusted HR 1·25, 95% CI 1·00-1·56, p=0·048 for total mortality; and 5·82, 1·64-20·65, p=0·0064 for aneurysm-related mortality). The increased aneurysm-related mortality in the EVAR group after 8 years was mainly attributable to secondary aneurysm sac rupture (13 deaths [7%] in EVAR vs two [1%] in open repair), with increased cancer mortality also observed in the EVAR group.EVAR has an early survival benefit but an inferior late survival compared with open repair, which needs to be addressed by lifelong surveillance of EVAR and re-intervention if necessary.UK National Institute for Health Research, Camelia Botnar Arterial Research Foundation.
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration’s Approach for Its Product Labeling
Authors: Sean D. Pokorney, Peter Shrader, Laine Thomas, Gregg C. Fonarow, Peter R. Kowey, Daniel E. Singer, Jack Ansell, Bernard J Gersh, Kenneth W. Mahaffey, Elaine M. Hylek, Alan S. Go, Jonathan P. Piccini, Eric D. Peterson
Journal: Circulation (2016)
Small Molecule Inhibitor of ITK Disrupts TCR Signaling and Demonstrates Anti-Tumor Efficacy
Authors: Mary Faris, Uriel M Malyankar, Qingping Zeng, Gary A Flynn, Gerold Feuer, Nathalie L Kertesz, Danka Vuga, Sandra Lee, Darlene Rosario, Adrian Bot
Journal: Blood (2010)
TCT-694 “Rural” United States Experience of Incorporation of a Technologically Advanced and Procedurally Complex Cardiovascular Program – The Sanford Trans-catheter Aortic Valve Replacement Experience
Authors: Amol Raizada, Tom P. Stys, Adam Stys, Jamal Dodin, Terezia Petraskova, Maria Molga
Journal: Journal of the American College of Cardiology (2015)
GW27-e0275 Genotype-Phenotype Analysis with Hypertrophic Cardiomyopathy in Chinese family with MYH7-V878A, CACNA1C-A1594V mutations
Authors: Guo Ruiqi, Bo Wang, Jing Wang, Fan Yang, Lei Zuo, Ying Liu, Hong Shao, Ju Yan, Lifeng Wang, Yanmin Zhang, Liwen Liu
Journal: Journal of the American College of Cardiology (2016)
Upregulation of Endogenous Erythropoietin (EPO) in Healthy Subjects by Inhibition of Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase.
Authors: P. Urquilla, A. Fong, S. Oksanen, S. Leigh, E. Turtle, L. Flippin, M. Brenner, E. Muthukrishnan, P. Fourney, A. Lin, D. Yeowell, C. Molineaux
Journal: Blood (2004)
Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features
Authors: Roberto Latagliata, Michele Cedrone, Nicoletta Villivà, Massimo Breccia, Barbara Anaclerico, Paola Volpicelli, Antonella Ferretti, Stefano Felici, Enrico Montefusco, Elisabetta Abruzzese, Antonio Spadea, Francesca Spirito, Ettore Cotroneo, Marianna De Muro, Luciana Annino, Giuseppe Cimino, Giuliana Alimena, Marco Montanaro, Alessandro Andriani
Journal: Blood (2010)
CD52 Is Expressed on Human Mast Cells and Is a Therapeutic Target for the Anti-CD52 Monoclonal Antibody Campath-1H in Waldenstrom’s Macroglobulinemia and Mast Cell Disorders.
Authors: Daniel Ditzel Santos, Evdoxia Hatjiarissi, Olivier Tournilhac, Lian Xu, Andrew Branagan, Zachary Hunter, Mayan Catsells, Kenneth C. Anderson, Steven P. Treon
Journal: Blood (2004)
Cryptogenic Organizing Pneumonia Following Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Minako Jinta, Kazuteru Ohashi, Chihiro Sakurai, Yuho Nashima, Masanori Tsuji, Kyoichi Harada, Miwa Sakai, Takuya Yamashita, Hideki Akiyama, Hisashi Sakamaki
Journal: Blood (2006)
TCT-563 Early vascular responses to everolimus-eluting cobalt-chronium stent for the treatment of ST-elevation acute myocardial infarction: the results of the MECHANISM-AMI study 3-months OCT follow-up cohort
Authors: Daisuke Terashita, Yoshihiro Morino, Hiromasa Otake, Tatsuo Kikuchi, Tetsuya Fusazaki, Nehiro Kuriyama, Takahide Suzuki, Toshiya Muramatsu, Kiyoshi Hibi, Hiroyuki Tanaka, Shozo Ishihara, toru kataoka, Takayuki Okamura, Takashi Morita, Yoritaka Otsuka, Takatoshi Hayashi, Kengo Tanabe, Toshiro Shinke, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2016)